ARID1A and ovarian carcinoma: Immunohistochemical analysis of ovarian cancer samples also confirmed a strong negative correlation between ARID1A expression and MRP2 expression (62), which provides an opportunity to overcome ARID1A deletion-induced chemoresistance in ovarian cancer by targeting MRP2.ARID1A deletion leads to resistance to PARP inhibitors in ovarian cancer patients (63), significantly increases chemoresistance in squamous cell carcinoma (64), promoting cell proliferation, metastasis, and resistance to sunitinib in clear cell renal cell carcinoma (65).